2. Search Result
Search Result
Results for "

SIRT-IN-1

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16615
    SIRT-IN-1

    		Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 μM, respectively.
    <em>SIRT-IN-1</em>
  • HY-16616
    SIRT-IN-2

    		Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC50s of 4, 4, 7 μM, respectively.
    <em>SIRT</em>-IN-2
  • HY-15145A
    SRT 1720 dihydrochloride
    30+ Cited Publications

    		 Sirtuin Autophagy Metabolic Disease
    SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .
    SRT 1720 dihydrochloride
  • HY-15145
    SRT 1720 monohydrochloride
    30+ Cited Publications

    		 Sirtuin Autophagy Metabolic Disease
    SRT 1720 monohydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .
    SRT 1720 monohydrochloride
  • HY-155729
    Sirt1/2-IN-4

    		Sirtuin Apoptosis Cancer
    Sirt1/2-IN-4 (compound PS3) is a triple inhibitor of SIRT1/2/3 with IC50s of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respsectivley. Sirt1/2-IN-4 completely blocks p53 deacetylation, with potential anti-cancer activity [1].
    <em>Sirt</em><em>1</em>/2-IN-4
  • HY-155784
    SPC-180002

    		Sirtuin Reactive Oxygen Species Keap1-Nrf2 Cancer
    SPC-180002 is a SIRT1/3 dual inhibitor, with IC50 values of 1.13 and 5.41 μM, respectively. SPC-180002 disturbs redox homeostasis via ROS generation, which leads to an increase in both p21 protein stability and mitochondrial dysfunction. SPC-180002 strongly inhibits cell cycle progression and cancer cell growth. SPC-180002 activates the Nrf2 signaling pathway [1].
    SPC-180002
  • HY-103636
    PROTAC Sirt2 Degrader-1

    		Sirtuin PROTACs Cancer
    PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s>100 μM) [1].
    PROTAC <em>Sirt</em>2 Degrader-<em>1</em>
  • HY-107453
    SirReal1-O-propargyl

    PROTAC SIRT2-bINdINg moiety 1

    		 Ligands for Target Protein for PROTAC Cancer
    SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC50 of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2 . SirReal1-O-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    SirReal<em>1</em>-O-propargyl
  • HY-155727
    Sirt1/2-IN-2

    		Sirtuin Apoptosis Cancer
    Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC50s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines [1].
    <em>Sirt</em><em>1</em>/2-IN-2
  • HY-155728
    Sirt1/2-IN-3

    		Sirtuin Apoptosis Cancer
    Sirt1/2-IN-3 (compound PS9) is a dual inhibitor of SIRT1/2 with IC50s of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respsectivley. Sirt1/2-IN-3 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-3 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines [1].
    <em>Sirt</em><em>1</em>/2-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: